IMAB - I-Mab Announces Participation at Jefferies and Piper Conferences in November

PR Newswire

ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35 ^th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

Jefferies London Healthcare Conference (In Person)

For more information, please contact your Jefferies representative.

Piper Sandler 35 ^th Annual Healthcare Conference (In Person)

For more information, please contact your Piper Sandler representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn , X, formerly known as Twitter , and WeChat .

I-Mab Contacts

SOURCE I-Mab